A real-world study of the renoprotective efficacy and safety of sodium-glucose co-transporter protein 2 inhibitors in the treatment of Chronic kidney disease patients without diabetes mellitus

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400079516

Enrollment

Unknown

Registered

2024-01-05

Start date

2024-02-01

Completion date

Unknown

Last updated

2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease without diabetes mellitus

Interventions

CKD patients without diabetes using SGLT-2i:none

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Must be >18 years of age at the time of signing the informed consent form and have a clinical diagnosis of chronic kidney disease

Exclusion criteria

Exclusion criteria: All types of diabetes

Design outcomes

Primary

Measure	Time frame
serum creatinine;Glomerular filtration rate;24-hour urine protein quantification;urinary albumin creatinine ratio;	—

Secondary

Measure	Time frame
Fasting blood glucose level;ß-Hydroxybutyric acid;blood lipid;electrolytes;urate;urine ketone body;plasma albumin;	—

Countries

China

Contacts

Public ContactFang Liu

Division of Nephrology, West China Hospital of Sichuan University

liufangfh@163.com+86 189 8060 1214

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026